The Quantellect read.As of Nov 19, 2026, 3 active firms cover Repro Med Systems Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $6.00 to $8.00, so the covering firms are broadly aligned. The average target of $7.33 sits 113% above the current $3.45. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.01 next quarter toward $0.06 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$7.33
+112.6% upside
Average target across 3 active firms as of Nov 19, 2026 vs $3.45 current
Highest Target$8.00
Average Target$7.33
Lowest Target$6.00
Detailed analyst forecasts for KRMD
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate KRMD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KRMD EPS & revenue forecast
EPS · NEXT QUARTER
$0.01
Range $0.01 – $0.02 · 2 analysts
Next period, 2 analysts expect Repro Med Systems Inc to earn $0.01 a share (range $0.01 – $0.02), versus $0.00 a year earlier. , growing to $0.06 the year after.
REVENUE · NEXT QUARTER
$13.5M
Range $13.0M – $13.8M · 2 analysts · +15% YoY
Revenue is expected to reach $13.5M (range $13.0M – $13.8M), +15.1% year-over-year. Full-year consensus is $48.2M, rising to $56.0M next year.
Top analysts covering Repro Med Systems Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KRMD.
#1
Chase Knickerbocker
Craig-Hallum · Rank #17
Buy
$6.00+73.9% to target
Overall win rate
61%
+ Follow
#2
Jason Bednar
Piper Sandler · Rank #360
Neutral
$5.00+44.9% to target
Overall win rate
33%
+ Follow
#3
Frank Takkinen
Lake Street · Rank #514
Buy
$8.00+131.9% to target
Overall win rate
27%
+ Follow
#4
CR
Caitlin Roberts
Canaccord Genuity
Buy
$6.00+73.9% to target
Coverage
—
+ Follow
#5
WW
William Woods
B. Riley Securities
Buy
$8.00+131.9% to target
Coverage
—
+ Follow
KRMD stock forecast FAQ
What is KRMD's average 12-month price target?+
The 3 active firms with a live target average $7.33 for Repro Med Systems Inc over the next 12 months, ranging from a $8.00 high to a $6.00 low, as of Nov 19, 2026.
Is KRMD stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KRMD?+
The Street-high target is $8.00 (B. Riley Securities), and the Street-low is $6.00 (Canaccord Genuity). The average of all 3 active-firm targets is $7.33.
How many active Wall Street firms cover KRMD?+
3 active firms have a recognized rating on Repro Med Systems Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KRMD?+
Among analysts who currently cover KRMD, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #17). Their current call is Buy with a $6.00 target.
What is Repro Med Systems Inc's projected EPS for next quarter?+
The consensus estimate is $0.01 per share (range $0.01 – $0.02) across 2 analysts. Full-year EPS is projected at —, rising to $0.06 the following year.
How much revenue is Repro Med Systems Inc expected to report next quarter?+
Consensus revenue is $13.5M (range $13.0M – $13.8M). Full-year revenue is projected at $48.2M, growing to $56.0M next year.
Have analysts been upgrading or downgrading KRMD lately?+
As of Nov 19, 2026, 3 of 3 active firms rate KRMD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KRMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.